Direct-Acting Small Molecule Therapeutic
In partnership with CARB-X, Bugworks is developing a novel first in class broad-spectrum antibiotic to kill multi-drug resistant Gram-negative bacteria that have been identified by the World Health Organization (WHO) as critical and high priority infection threats. Our lead compound, a Gyrase-topoisomerase inhibitor, is being developed as an intravenous and oral treatment for multi-drug resistant infections, with a low risk of developing resistance because it inhibits two essential targets in the replication machinery and has been designed to by-pass efflux resistance mechanism of the bacteria. In pre-clinical testing, Bugworks’ novel broad-spectrum antibiotics have demonstrated efficacy against deadly Gram-negative superbugs. Bugworks is based in Delaware, US, and operates its R&D facilities in Bangalore, India.
Current Development Stage: Lead Optimization
CARB-X Investment: Initial investment of up to $2.6m with potential option payments up to $3.6m.
Initial CARB-X Investment Date: July 1, 2017